Ma Iune 30, ua loaʻa i ka mea hoʻopaʻa MET Vebreltinib i hoʻomohala kūʻokoʻa ʻia e Avistone ka ʻae ʻia mai ka National Medical Products Administration (NMPA) o Kina no ka mālama ʻana i nā maʻi me ka maʻi kanesa māmā non-small cell (NSCLC) i holomua kūloko a i ʻole metastatic me ka hoʻonui ʻana o ka MET. ʻO kēia ka hōʻailona ʻekolu i ʻae ʻia no Vebreltinib ma Kina a ʻo ka lāʻau lapaʻau hoʻokahi-agent mua loa o ka honua i ʻae kūikawā ʻia no nā maʻi NSCLC i hoʻonui ʻia e ka MET.
ʻO ka ʻāpono ʻia ʻana o Vebreltinib ma Kina no kēia hōʻailona hou—e mālama ana i nā maʻi me ka maʻi kanesa māmā non-small cell (NSCLC) i holomua a i ʻole metastatic me ka hoʻonui ʻana o ka MET—ua hoʻokumu ʻia ma nā hopena maikaʻi mai Cohort 2 a me Cohort 3 o ke aʻo ʻana ʻo KUNPENG (NCT04258033).
Ua hoʻopaʻa inoa nui ʻo Cohort 2 i nā maʻi i mālama mua ʻia me ka MET-amplified NSCLC i hāʻule ʻole i ka lāʻau lapaʻau maʻamau (me ka chemotherapy e pili ana i ka platinum), ʻoiai ʻo Cohort 3 i hoʻokomo nui ʻia i nā maʻi i hoʻomaka mua i ka lāʻau lapaʻau me ka MET-amplified NSCLC i hōʻole i ka chemotherapy.
Ua kākau inoa ʻia he 86 mau maʻi me ka NSCLC holomua kūloko a metastatic paha ma nā cohorts ʻelua (33 ma Cohort 2 a me 53 ma Cohort 3). Ua hōʻike nā hopena o ke aʻo ʻana i ka helu pane holoʻokoʻa (ORR) o 48.8%, ka helu kaohi maʻi (DCR) o 77.9%, ka lōʻihi waena o ka pane (DoR) o 12.1 mau mahina, ka awelika o ka holomua ʻole o ke ola (PFS) o 7.4 mau mahina, a me ka awelika o ka ola holoʻokoʻa (OS) o 13.9 mau mahina.
Ma Cohort 2 (33 mau maʻi i mālama mua ʻia), ʻo ka ORR he 48.5%, ʻo DCR he 78.8%, ʻo ka awelika DoR he 11.0 mahina, ʻo ka awelika PFS he 6.2 mahina, a ʻo ka awelika OS he 11.7 mahina.
I loko o Cohort 3 (53 mau maʻi i hoʻomaka mua i ka mālama ʻana), ʻo ka ORR he 49.1%, ʻo DCR he 77.4%, ʻo ka awelika DoR he 12.1 mahina, ʻo ka awelika PFS he 8.3 mahina, a ʻo ka awelika OS he 15.5 mahina.
Ma ke aʻo ʻana ʻo KUNPENG, ua loiloi ʻia he 21 mau maʻi me nā metastases o ka lolo baseline e ke Kōmike Loiloi Kūʻokoʻa (IRC). Ma waena o kēia mau mea, ua loaʻa i ka 10 nā pane hapa i hōʻoia ʻia (PR), e hopena ana i ka ORR o 47.6%, DCR o 85.7%, a me ka DoR waena o 11.0 mau mahina. Eia kekahi, ʻo ka PFS waena a me OS he 8.3 mau mahina a me 14.7 mau mahina, kēlā me kēia.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Ka manawa hoʻouna: Iulai-08-2025